Cumulative incidence of relapse based on dexamethasone clearance and anti–asparaginase antibody status. Cumulative incidence of CNS relapse (A) and any (hematologic, CNS, combined, and other) relapse (B) in patients who became positive (N = 207) versus those who remained negative (N = 132) for anti–asparaginase (ASP) antibodies with P values based on multivariate analysis (Table 1). Cumulative incidence of CNS relapse (C) and any relapse (D) in patients with dexamethasone (Dex) clearance (CL) greater than (N = 12) versus lower (N = 327) than 37.5 L/h per m² with P values based on log-rank test.